{
    "clinical_study": {
        "@rank": "89037", 
        "acronym": "Precision-UC", 
        "arm_group": [
            {
                "arm_group_label": "TP05 (Mesalazine)", 
                "arm_group_type": "Experimental", 
                "description": "3.2g/day once daily for 12 weeks (blinded) 1.6g/day - 4.8g/day up to week 38 (OpenLabel)"
            }, 
            {
                "arm_group_label": "Asacol (Mesalazine, Tillotts Pharma AG)", 
                "arm_group_type": "Active Comparator", 
                "description": "3.2g/d twice daily for 12 weeks (blinded), switch to TP05 weeks 13-38 (open label)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this research study is to compare the medication TP05 to the medication\n      Asacol\u2122 for the treatment of ulcerative colitis (UC) and to assess the safety and\n      tolerability of TP05. This study will investigate whether TP05 is as good as (non-inferior\n      to) Asacol\u2122."
        }, 
        "brief_title": "TP05 for the Treatment of Mild to Moderate Active UC", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Ulcerative Colitis", 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Ulcer"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 3, randomised, double-blind, active-controlled, multi-centre,\n      non-inferiority trial to evaluate the safety and efficacy of 3.2 g of TP05/day compared to\n      3.2 g/day of Asacol\u2122 with an open label extension to assess the long-term safety and\n      tolerability of TP05 administered over a 26 week period. A total of 800 subjects with mildly\n      to moderately active UC will be evaluated. Eligible subjects will be randomly assigned in a\n      1:1 ratio to receive 3.2 g/day of TP05 (administered once daily) or 3.2 g/day of Asacol\u2122.\n      The primary efficacy outcome will be assessed at Week 8.  All subjects who respond to\n      TP05/Asacol\u2122 (response or remission) will continue receiving blinded study treatment for up\n      to 12 weeks. After that, subjects can enroll in an Open Label Extension (OLE) for 26 weeks\n      duration to receive TP05. Subjects failing to respond to study drug at the Week 8 visit can\n      enroll in the OLE at week 8 and receive 4.8 g/day of TP05."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Induction phase - Main criteria for inclusion include:\n\n          1. Male or non-pregnant, non-lactating females, 18 years of age or older.  Females of\n             child bearing potential must have a negative serum pregnancy test prior to\n             randomisation, and must use a hormonal (oral, implantable or injectable) or barrier\n             method of birth control throughout the study.  Females unable to bear children must\n             have documentation of such in the source records (i.e., tubal ligation, hysterectomy,\n             or post-menopausal [defined as a minimum of one year since the last menstrual\n             period]).\n\n          2. Documented diagnosis of UC with disease extending at least 15 cm from the anal verge.\n\n          3. Active UC defined by:\n\n               1. Mayo score of > 5\n\n               2. Sigmoidoscopy component score \u2265 2 confirmed by central review and\n\n               3. Rectal bleeding component score \u2265 1\n\n          4. Ability of the subject to participate fully in all aspects of this clinical trial.\n\n          5. Written informed consent must be obtained and documented.\n\n        Induction Phase - Main criteria for exclusion include:\n\n        Subjects who exhibit any of the following conditions are to be excluded from the study:\n\n        (1) Severe UC defined by the following criteria: 6 bloody stools daily with one or more of\n        the following:\n\n          1. oral temperature > 37.8 degrees C or > 100.0 degrees F\n\n          2. pulse > 90 beats/min\n\n          3. haemoglobin < 10 g/dL (2) Treatment with oral mesalamine at a dose of > 2.4 g/day\n             within 4 weeks prior to randomisation.\n\n             (3) Treatment with topical therapy (mesalamine or corticosteroids) within 2 weeks\n             prior to randomisation (4) Treatment with systemic or rectal steroids within 4 weeks\n             prior to randomisation.\n\n             (5) Treatment with immunosuppressants within 6 weeks prior to randomisation. (6)\n             Treatment with infliximab or other biologics within 3 months prior to randomisation.\n\n             (7) Treatment with  antibiotics within 7 days prior to randomisation. (8) Treatment\n             with probiotics within 7 days prior to randomisation. (9) Treatment with\n             anti-diarrhoeal treatment within 7 days prior to randomisation.\n\n             (10) Treatment with nicotine patch within 7 days prior to randomisation. (11)\n             Received any investigational drug within 30 days prior to randomisation. (12) History\n             of colectomy or partial colectomy. (13) History of definite dysplasia in colonic\n             biopsies. (14) Crohn's disease. (15) Immediate or significant risk of toxic\n             megacolon. (16) Known bleeding disorders. (17) Hypersensitivity to salicylates,\n             aspirin, sulfasalazine or mesalazine. (18) Serum creatinine > 1.5 times the upper\n             limit of the normal range. (19) Aspartate aminotransferase (AST), alanine\n             aminotransferase (ALT), total bilirubin or alkaline phosphatase > 2 times the upper\n             limit of the normal range.\n\n             (20) Serious underlying disease other than UC which in the opinion of the\n             investigator may interfere with the subject's ability to fully participate in the\n             study.\n\n             (21) History of alcohol or drug abuse which in the opinion of the investigator may\n             interfere with the subject's ability to comply with the study procedures.\n\n             (22) Stools positive for Clostridium difficile toxin. (23) Pregnant or lactating\n             women. (24) Prior enrolment in the study.\n\n             OLE - Main criteria for inclusion include:\n\n               1. Attendance at the Week 8 visit and completion of disease activity assessments\n                  prior to enrolment in OLE at Week 12 (responders or remitters) or Week 8\n                  (non-responders).\n\n               2. At least 75% compliance with study medication in the induction phase.\n\n             OLE - Main criteria for exclusion include:\n\n             (1) Withdrawal from the induction phase prior to the Week 8 visit."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "800", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01903252", 
            "org_study_id": "TP0503"
        }, 
        "intervention": [
            {
                "arm_group_label": "TP05 (Mesalazine)", 
                "description": "3.2g/day once daily for 12 weeks (blinded), 1.6g/d - 4.8g/d up to week 38 (open label)", 
                "intervention_name": "TP05", 
                "intervention_type": "Drug", 
                "other_name": "Mesalazine"
            }, 
            {
                "arm_group_label": "Asacol (Mesalazine, Tillotts Pharma AG)", 
                "description": "3.2g/d twice daily for 12 weeks (blinded), switch to 1.6g/ - 4.8g/d TP05 up to week 38 (open label)", 
                "intervention_name": "Asacol", 
                "intervention_type": "Drug", 
                "other_name": "Mesalazine (Tillotts Pharma AG)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Mesalamine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "UC", 
        "lastchanged_date": "August 20, 2013", 
        "location": {
            "contact": {
                "email": "gdhaens@amc.uva.nl", 
                "last_name": "Geert R D'Haens, MD", 
                "phone": "+31205663534"
            }, 
            "facility": {
                "address": {
                    "city": "Amsterdam", 
                    "country": "Netherlands", 
                    "state": "Pietersbergweg", 
                    "zip": "1105 BM"
                }, 
                "name": "Robarts Clinical Trials Inc"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised,Active-Controlled, Double-Blind and Open Label Extensions Study to Evaluate the Efficacy, Long-Term Safety and Tolerability of TP05 3.2g/d for the Treatment of Active Ulcerative Colitis", 
        "overall_contact": {
            "email": "gdhaens@amc.uva.nl", 
            "last_name": "Geert R D'Haens, MD", 
            "phone": "+3129-5663-534"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Belarus: Ministry of Health", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Canada: Canadian Institutes of Health Research", 
                "Czech Republic: State Institute for Drug Control", 
                "Denmark: Danish Health and Medicines Authority", 
                "Finland: Finnish Medicines Agency", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Ireland: Irish Medicines Board", 
                "Norway: Norwegian Medicines Agency", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Sweden: Medical Products Agency", 
                "Ukraine: Ministry of Health", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Mayo Score of <= 2 points with no individual sub-score > 1", 
            "measure": "Clinical and endoscopic remission", 
            "safety_issue": "No", 
            "time_frame": "8 weeks Induction"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01903252"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Maintenance of remission, open label", 
                "measure": "safety", 
                "safety_issue": "No", 
                "time_frame": "week 38"
            }, 
            {
                "measure": "proportion of patients in remission", 
                "safety_issue": "No", 
                "time_frame": "week 38"
            }
        ], 
        "source": "Tillotts Pharma AG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tillotts Pharma AG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}